Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1708 PK and Itraconazole Interaction Study
NCT06586606Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of mk-1708 in Alzheimer's disease (AD) (2 arms), sponsored by Merck & Co. Primary endpoints: Area Under the Concentration-Time Curve from Time 0 to Infinity at 2 weeks, Number of Participants Who Experience an Adverse Event at 11 weeks and 1 more. Started Oct 2024; status: completed.
02
Drugs
mk-1708
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06586606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06586606.